Fosun contributed $50M to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering.
December 29, 2017 -- Shanghai Henlius Biotech boosted its cash level by selling 55.4 million shares to bring in $192.5 million. Shanghai Helius, a joint venture formed by Henlius Biotech and Shanghai Fosun Pharma in 2009, is developing a portfolio of biosimilars, bio-betters and novel biotech drugs. Fosun contributed $50 million to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering. Henlius says it has submitted eight INDs to the CFDA with thirteen indications. Its two lead drugs have started Phase III trials.
